Global Gene Therapy Market Overview:
Global Gene Therapy Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2025-2032, Considering the Base Year As 2024.
Global Gene Therapy Market Report 2025 comes with the extensive industry analysis with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Gene Therapy involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Gene Therapy Market:
The Gene Therapy Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Gene Therapy Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Gene Therapy Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Gene Therapy market has been segmented into:
Viral
Non-Viral
By Application, Gene Therapy market has been segmented into:
Oncological Disorders
Rare Diseases
Cardiovascular Diseases
Neurological Disorders
Infectious Diseases
Other Applications).
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Gene Therapy market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Gene Therapy market.
Top Key Players Covered in Gene Therapy market are:
Amgen Inc.
Alnylam Pharmaceuticals Inc.
Bionomics Ltd.
BioMarin Pharmaceutical Inc.
AnGes Inc.
Amicus Therapeutics Inc.
Arrowhead Pharmaceuticals Inc.
bluebird bio Inc.
Advantagene Inc.
Biogen Inc.
Abeona Therapeutics
Aptah
Avrobio
Arbor Biotechnologies Inc.
Biocardia Inc.
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Gene Therapy Market Type
4.1 Gene Therapy Market Snapshot and Growth Engine
4.2 Gene Therapy Market Overview
4.3 Viral
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Viral: Geographic Segmentation Analysis
4.4 Non-Viral
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Non-Viral: Geographic Segmentation Analysis
Chapter 5: Gene Therapy Market Application
5.1 Gene Therapy Market Snapshot and Growth Engine
5.2 Gene Therapy Market Overview
5.3 Oncological Disorders
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Oncological Disorders: Geographic Segmentation Analysis
5.4 Rare Diseases
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Rare Diseases: Geographic Segmentation Analysis
5.5 Cardiovascular Diseases
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Cardiovascular Diseases: Geographic Segmentation Analysis
5.6 Neurological Disorders
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Neurological Disorders: Geographic Segmentation Analysis
5.7 Infectious Diseases
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Infectious Diseases: Geographic Segmentation Analysis
5.8 Other Applications).
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.8.3 Other Applications).: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Gene Therapy Market Share by Manufacturer (2025)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 AMGEN
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 INC.; ALNYLAM PHARMACEUTICALS
6.4 INC.; BIONOMICS LTD.; BIOMARIN PHARMACEUTICAL
6.5 INC.; ANGES
6.6 INC.; AMICUS THERAPEUTICS
6.7 INC.; ARROWHEAD PHARMACEUTICALS
6.8 INC.; BLUEBIRD BIO
6.9 INC.; ADVANTAGENE
6.10 INC.; BIOGEN
6.11 INC.; ABEONA THERAPEUTICS; APTAH; AVROBIO; ARBOR BIOTECHNOLOGIES
6.12 INC.; BIOCARDIA
6.13 INC.
Chapter 7: Global Gene Therapy Market By Region
7.1 Overview
7.2. North America Gene Therapy Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Viral
7.2.2.2 Non-Viral
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Oncological Disorders
7.2.3.2 Rare Diseases
7.2.3.3 Cardiovascular Diseases
7.2.3.4 Neurological Disorders
7.2.3.5 Infectious Diseases
7.2.3.6 Other Applications).
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Gene Therapy Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Viral
7.3.2.2 Non-Viral
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Oncological Disorders
7.3.3.2 Rare Diseases
7.3.3.3 Cardiovascular Diseases
7.3.3.4 Neurological Disorders
7.3.3.5 Infectious Diseases
7.3.3.6 Other Applications).
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Gene Therapy Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Viral
7.4.2.2 Non-Viral
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Oncological Disorders
7.4.3.2 Rare Diseases
7.4.3.3 Cardiovascular Diseases
7.4.3.4 Neurological Disorders
7.4.3.5 Infectious Diseases
7.4.3.6 Other Applications).
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Gene Therapy Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Viral
7.5.2.2 Non-Viral
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Oncological Disorders
7.5.3.2 Rare Diseases
7.5.3.3 Cardiovascular Diseases
7.5.3.4 Neurological Disorders
7.5.3.5 Infectious Diseases
7.5.3.6 Other Applications).
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Gene Therapy Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Viral
7.6.2.2 Non-Viral
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Oncological Disorders
7.6.3.2 Rare Diseases
7.6.3.3 Cardiovascular Diseases
7.6.3.4 Neurological Disorders
7.6.3.5 Infectious Diseases
7.6.3.6 Other Applications).
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Gene Therapy Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Viral
7.7.2.2 Non-Viral
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Oncological Disorders
7.7.3.2 Rare Diseases
7.7.3.3 Cardiovascular Diseases
7.7.3.4 Neurological Disorders
7.7.3.5 Infectious Diseases
7.7.3.6 Other Applications).
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Gene Therapy Scope:
|
Report Data
|
Gene Therapy Market
|
|
Gene Therapy Market Size in 2025
|
USD XX million
|
|
Gene Therapy CAGR 2025 - 2032
|
XX%
|
|
Gene Therapy Base Year
|
2024
|
|
Gene Therapy Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Amgen Inc., Alnylam Pharmaceuticals Inc., Bionomics Ltd., BioMarin Pharmaceutical Inc., AnGes Inc., Amicus Therapeutics Inc., Arrowhead Pharmaceuticals Inc., bluebird bio Inc., Advantagene Inc., Biogen Inc., Abeona Therapeutics, Aptah, Avrobio, Arbor Biotechnologies Inc., Biocardia Inc..
|
|
Key Segments
|
By Type
Viral
Non-Viral
By Applications
Oncological Disorders
Rare Diseases
Cardiovascular Diseases
Neurological Disorders
Infectious Diseases
Other Applications).
|
